An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

BACKGROUND. Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This study examined the safety of the triplet co...

詳細記述

保存先:
書誌詳細
主要な著者: Esteva, Francisco J., Franco, Sandra X., Hagan, Maura K., Brewster, Abenaa M., Somer, Robert A., Williams, Will, Florance, Allison M., Turner, Simon, Stein, Steven, Perez, Alejandra
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2013
主題:
Breast Cancer
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063391/
https://ncbi.nlm.nih.gov/pubmed/23697602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0129
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料